Submit previous trial data for Covaxin before rolling out phase III: Drug regulator to Bharat Biotech
According to the Subject Expert Committee (SEC) meeting, the firm presented the phase III clinical trial protocol along with interim data of phase I and II clinical trials on October 2.
The technology is being used under licensing agreement with the USA-based ViroVax LLC.
Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated at the National Institute of Virology (NIV), Pune, an Indian virology research institute.
The total cases include 9,42,217 active cases, 53,52,078 cured/discharged/migrated & 99,773 deaths, according to the Ministry of Health & Family Welfare's latest update.
COVID-19 HIGHLIGHTS | Rajasthan imposes section 144 in eleven districts due to rising coronavirus cases
Section 144 CrPC imposed in Jaipur, Jodhpur, Kota, Ajmer, Alwar, Bhilwara, Bikaner, Udaipur, Sikar, Pali & Nagaur due to increasing COVID case, announced Rajasthan CM Ashok Gehlot.
The prime minister has been regularly holding meetings to review the pandemic situation across the country with a focus on states/UTs where the situation is more serious.
Some states are reportedly mandating manufacturers and suppliers located in the state to restrict their oxygen supplies to the hospitals of the state.
COVID-19 HIGHLIGHTS | India crosses six crore mark in testing; 11,36,613 samples taken in single day
Recently, increasing number of cases were reported from states like Maharashtra, Andhra Pradesh, Karnataka and Tamil Naidu.
In terms of recoveries, India is in the pole position, followed by Brazil and the US, according to the Johns Hopkins University which has been compiling COVID-19 data from all over the world.
In the first phase, 12 sites were selected across the country for human clinical trial of Covaxin developed by Hyderabad-based Bharat Biotech International.
It was mandatory for all legislators to carry their COVID-19 test report to attend the House proceedings.
The two-dose vaccination candidates was found to induce a strong immune response and protection of animals from the infection of SARS-CoV-2, the researchers said.
The death toll due to the pandemic in Mumbai increased by 38 to reach 8,023.
Dr Vinod K Paul said that Bharat Biotech's vaccine candidate based on inactivated virus procured by ICMR and Zydus Cadila's candidate based on viral DNA are two Indian vaccines in second phase trial.
According to the Delhi government latest health bulletin, the death toll mounted to 4,618, after 19 more fatalities were recorded in the last 24 hours.